STOCKHOLM — British pharmaceuticals giant AstraZeneca wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. [nS8N1JA01C]Advertisement Continue reading the main storyForeign Secretary Boris Johnson has said the transition period must not last more than two years. Newsletter Sign Up Continue reading the main story Please verify you're not a robot by clicking the box. Sign Up You agree to receive occasional updates and special offers for The New York Times's products and services. AstraZeneca was preparing for a situation where there was no deal but did not yet have concrete plans, Johansson said.

Source: New York Times October 02, 2017 09:56 UTC